

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

MALLINCKRODT PLC.,

Reorganized Debtor.¹

Chapter 11

Case No. 20-12522 (BLS)

**NOTICE OF FILING OF PERIODIC REPORT OF THE OPIOID MASTER
DISBURSEMENT TRUST II**

TO OPIOID CREDITOR TRUSTEES, THE FUTURE CLAIMANTS' REPRESENTATIVE,
AND ALL OTHER INTERESTED PARTIES:

PLEASE TAKE NOTICE that, in accordance with Section 3.02(b) of the Opioid Master Disbursement Trust II Trust Agreement dated as of June 16, 2022 (the "Trust Agreement"), Jennifer E. Peacock, Michael Atkinson, and Anne Ferazzi, in their capacities as the Opioid Master Disbursement Trust II Trustees (the "Trustees"), have filed a periodic report (the "Periodic Report"), attached hereto as **Exhibit 1**. As further required by Section 3.02(c) of the Trust Agreement, the Periodic Report will be posted on the Opioid Master Disbursement Trust II website at www.opioidmasterdisbursementtrust.com/Mallinckrodt.

¹ The Reorganized Debtor in this chapter 11 case is Mallinckrodt plc ("**Mallinckrodt**"). On May 3, 2023, the Court entered an order closing the chapter 11 cases of the Reorganized Debtor's debtor-affiliates (together with Mallinckrodt, "**Debtors**"). A complete list of the Debtors in these Chapter 11 cases may be obtained on the website of the Reorganized Debtor's claims and noticing agent at <http://restructuring.ra.kroll.com/Mallinckrodt>. The Reorganized Debtor's mailing address is 675 McDonnell Blvd., Hazelwood, Missouri 63042.

Dated: February 13, 2026

Respectfully submitted,

COLE SCHOTZ P.C.

/s/ Justin R. Alberto

Justin R. Alberto (No. 5126)
500 Delaware Avenue, Suite 600
Wilmington, DE 19801
Telephone: (302) 652-3131
Facsimile: (302) 652-3117
jalberto@coleschotz.com

Anthony De Leo, Esq.
1325 Avenue of the Americas
19th Floor
New York, NY 10019
Telephone: (212) 752-8000
Facsimile: (212) 752-8393
adeleo@coleschotz.com

-and-

BROWN RUDNICK LLP

David J. Molton, Esq.
Gerard T. Cicero, Esq.
Seven Times Square
New York, NY 10036
Telephone: (212) 209-4800
Facsimile: (212) 209-4801
dmolton@brownrudnick.com
gcicero@brownrudnick.com

*Co-Counsel to the Opioid Master Disbursement
Trust II*

EXHIBIT 1

Periodic Report Ending January 31, 2026

Opioid Master Disbursement Trust II
Table of Contents
For the Reporting Period Ending January 31, 2026

Section	Page Number
<i>Introduction</i>	2
<i>Reporting Period Activity</i>	2
<i>Financial Update</i>	4
<i>Legal Matters Update</i>	4
<i>Exhibit A</i>	10
<i>Appendix</i>	12
<i>Appendix 1: Trust Financial Summary</i>	13
<i>Appendix 2: Trust Budget</i>	16

Opioid Master Disbursement Trust II

Report for Period October 1, 2025, through January 31, 2026

Introduction

Pursuant to Section 3.02 of the MDT II Trust Agreement, the Opioid Master Disbursement Trust II (“MDT II” or “the Trust”) is obligated to report to each of the Opioid Creditor Trusts and the Future Claimants’ Representative,¹ at least every four months, on topics including the Trust’s:

- Assets;
- Expenditures;
- Distributions;
- Forward-looking projections; and
- Litigation proceedings.

The following report, for the period beginning October 1, 2025, and ending January 31, 2026 (the “Period”),² fulfills such obligation. Further background on the Trust is provided in Exhibit A.

Reporting Period Activity

Monetization Under the CVR Agreement

During the Period, MDT II reached an agreement with Mallinckrodt to terminate the Contingent Value Right Agreement.

¹ Capitalized terms used but not defined herein shall have the meaning ascribed to them in the Chapter 11 Plan confirmed in the bankruptcy cases of Mallinckrodt plc, *In re Mallinckrodt plc*, Case No. 20-12522 (Bankr. D. Del.) (the “Plan”).

² MDT II’s prior reports are available on both the *In re Mallinckrodt* docket and the MDT II website (<https://www.opioidmasterdisbursementtrust.com/Mallinckrodt/PeriodicReports>).

Opioid Master Disbursement Trust II

By way of background, on March 13, 2025, Mallinckrodt announced its intention to merge with Endo, and the merger was completed on August 1, 2025. As part of the merger, Mallinckrodt-Endo announced it is planning to spin off its combined generics business before the end of 2025. In connection with Mallinckrodt's second bankruptcy in 2023, MDT II negotiated for and entered into the CVR Agreement with the company, which provided for additional consideration to flow to MDT II's beneficiaries provided certain contingencies were satisfied.

Following several weeks of negotiation, the MDT II Trustees obtained a \$35 million payment in exchange for the termination of the CVR Agreement.

MDT II subsequently disbursed the full amount, less \$400,000 in transaction costs, consistent with the 2022 Plan.

Extension of the Other Opioid Claims Objection Deadline

During the Period, MDT II continued to engage with those entities having filed Other Opioid Claims to resolve these claims as efficiently as possible. A stipulation was filed earlier this year with opioid distributor McKesson that it is not seeking any affirmative relief and that any rights are limited to any additional insured rights under insurance policies purchased by the Debtors and Co-Defendant Defensive Rights. MDT II also filed a motion to reclassify Other Opioid Claim filed by IQVIA Inc. as a Class 9(i) No Recovery Opioid Claim, which was resolved by stipulation with IQVIA. At this time, it is not anticipated that any of the remaining claims will have a material impact on the assets of the Trust. The current objection deadline for Other Opioid Claims is the later of: (a) March 12, 2026, or (b) one hundred twenty (120) days following the date that a proof of Other Opioid Claim is amended in writing by or on behalf of a holder of such Other Opioid Claim.

Opioid Master Disbursement Trust II

Financial Update

During the Period, the Trust began with a cash balance of \$95,404,065; received \$36,271,569; and disbursed \$38,741,610; resulting in an ending Trust cash balance of \$92,934,024.

The Trust's receipts during the Period were comprised of (i) \$1,271,569 of interest and other income (~3.90% annualized rate), and (ii) \$35,000,000 of proceeds in exchange for termination of the contingent value rights ("CVR") agreement. The Trust's disbursements during the Period were comprised of (i) \$4,141,610 on account of Trust expenses and (ii) \$34,600,000 to opioid creditor trusts.

At this time, all assets are held in short term U.S. Government obligations.

Legal Matters Update

Under the Plan, the Trust was assigned certain claims against third parties. The claims being pursued are described in greater detail below.

1. Insurance Action (*Opioid Master Disbursement Trust II a/k/a Opioid MDT II v. Ace American Insurance Company, et al.*, Case No. 22SL-CC02974 (Mo. Cir. Ct.))

On June 16, 2022, the Trust filed a lawsuit in St. Louis County, Missouri, against insurers that had issued certain policies under which rights were transferred to the Trust pursuant to the Plan, seeking insurance coverage with respect to the opioid-related claims that were channeled to the Trust and Opioid Creditor Trusts under the Plan. On December 20, 2023, the Trust filed a separate but related lawsuit involving certain additional insurance policies that it had discovered through a third-party subpoena. On the Trust's motion, these two lawsuits were consolidated on January 30, 2024. By final order dated March 5, 2024, certain insurance policies were dismissed with prejudice from this lawsuit due to a forum-selection clause in or incorporated in those policies that the insurers contended mandates exclusive jurisdiction over any coverage disputes in the courts of England or Wales.

Opioid Master Disbursement Trust II

On April 16, 2024, the Trust filed a motion for partial summary judgment regarding exclusions in most of the policies in the Missouri lawsuit for bodily injury included within the so-called “products hazard”. The products hazard applies only to bodily injury arising out of “your [Mallinckrodt’s] products”. The Trust contends that the products hazard exclusions therefore do not exclude bodily injury arising in whole or in part from opioid pharmaceuticals not manufactured or sold by Mallinckrodt, or from illicit opioid drugs, for which Mallinckrodt was alleged to be liable because of its role in causing and fueling the nationwide opioid crisis due to its widespread promotion of opioids as a class of drugs appropriate for treatment of long-term chronic pain. On July 17, 2024, the insurers filed cross motions, arguing that the exclusions eliminate coverage under these policies.

On March 10, 2025, the court entered summary judgment against the Trust and in favor of the insurers. Because the court’s ruling resolved a substantial portion of the coverage in the case, the Trust moved for, and the court granted, interlocutory appeal of this decision (that is, immediate appeal without waiting for the rest of the case to be resolved). The Trust filed its brief with the Missouri Court of Appeals on November 24, 2025, and insurers filed their responses on January 21, 2026. Our reply is due to be filed on February 25, 2026 and oral argument on the appeal is currently scheduled for May 7, 2026.

On June 13, 2025, at the request of the parties, the court issued a partial stay of discovery pending resolution of the appeal. Pursuant to the stay order, fact discovery will continue for at least ten months after the appeal is decided (this is true whether or not the Trust prevails on appeal, since there is significant coverage in the case that is not subject to the products hazard ruling or the related appeal). While the appeal is pending, the parties will continue to address existing document discovery and may bring any discovery disputes arising out of the parties’ pending discovery to the court. The parties may also propound discovery requests on third parties during the pendency of the appeal.

Opioid Master Disbursement Trust II

The next case management conference will be scheduled following a decision on the pending appeal.

2. Covidien Spinoff Action (*Opioid Master Disbursement Trust II v. Covidien Unlimited Co., et al.*, Adv. Pro. No. 22-50433 (Bankr. D. Del.))

On October 11, 2022, the Trust commenced an adversary proceeding in the U.S. Bankruptcy Court for the District of Delaware against Covidien Unlimited Company, Mallinckrodt's former parent, and three of its subsidiaries, hereinafter referred to, collectively, as "Covidien." On January 18, 2024, the Trust won a key opening victory, surviving Covidien's motion to dismiss. The Court allowed the majority of the Trust's claims, namely for intentional fraudulent transfer, reimbursement, indemnification, contribution, equitable subordination, and disallowance pursuant to Sections 502(d) and 502(e) of the Bankruptcy Code, to proceed. The Court dismissed the claims for constructive fraudulent transfer, breach of fiduciary duty as a promoter, and equitable disallowance. The Court also granted the motion to amend with respect to the claims that it allowed to proceed. Covidien filed its answer on March 25, 2024.

Through the surviving claims, the Trust seeks to avoid and recover (a) the value of the entire Covidien enterprise (without the Mallinckrodt business) at the time of the 2013 spinoff of Mallinckrodt from Covidien; (b) approximately \$867 million in net cash transfers that Mallinckrodt paid to Covidien from 2010 through 2012; and (c) approximately \$721 million in Mallinckrodt note proceeds that Covidien received before completing the spinoff. In addition, the Trust seeks to avoid (i) the putative indemnification obligations that Covidien imposed on Mallinckrodt under the spinoff agreement and (ii) certain pre-spin tax liabilities in the hundreds of millions of dollars that Covidien imposed on Mallinckrodt in connection with the spinoff, and to recover from Covidien (iii) the value of any payments that Mallinckrodt made on account of those pre-spinoff tax liabilities. The Trust also has a claim for reimbursement, indemnification, and contribution for the opioid-related costs incurred by Mallinckrodt.

The Court allowed Covidien to file an initial summary judgment motion limited to 11 U.S.C. § 546(e) issues and the Court heard oral argument on May 9, 2025. On August 20, 2025,

Opioid Master Disbursement Trust II

the Court denied the entire motion for summary judgment except for Count I as to Covidien S.à r.l – one of the four defendants. Covidien S.à r.l. remains a defendant on all other counts of the amended complaint.

Discovery is continuing, and the parties are engaged in mediation over Covidien's discovery obligations. Although fact discovery is currently scheduled to be completed by March 31, 2026, the Trust expects that the parties will soon negotiate a new schedule, based on the outcome of the mediation, that will extend the fact discovery deadline until later in 2026. The Trust is also litigating over Covidien's parent company Medtronic's refusal to respond to the Trust's latest request for production of documents.

3. Share Repurchase Program Action (*Opioid Master Disbursement Trust II v. Argos Capital Appreciation Master Fund LP, et al.*, Adv. Pro. No. 22-50435 (Bankr. D. Del.))

On October 12, 2022, the Trust commenced an adversary proceeding in the U.S. Bankruptcy Court for the District of Delaware against 72 defendant participants in Mallinckrodt plc's share repurchase program (the "SRP"). On October 24, 2023, the Trust amended its complaint to add 43 additional Defendants that were identified during the Trust's investigation. To date, the Trust has also voluntarily dismissed 59 Defendants. In addition, the Court entered summary judgment in favor of 38 Defendants.

The Trust asserts causes of action for intentional and constructive fraudulent transfers through which it seeks to avoid and recover some of the over \$1 billion in cash transfers Mallinckrodt plc paid to its equity owners through the SRP between 2015 and 2018. The Trust asserts that the shares Mallinckrodt purchased through the SRP were worthless because Mallinckrodt was deeply insolvent at the time of the repurchases due to massive liabilities incurred from the manufacture, promotion, and distribution of opioid products. The Trust asserts that the cash paid to Mallinckrodt shareholders through the SRP was wrongly diverted and should be recouped for the benefit of Mallinckrodt's creditors.

On May 15, 2023, the Court approved a protocol whereby Defendants may assert individual affirmative defenses to the claims alleged in the SRP action, including that a given Defendant is protected by the safe-harbor provisions of 11 U.S.C. § 546(e) or

Opioid Master Disbursement Trust II

received the proceeds of share repurchase transactions as a mere conduit. The Trust has been responding to Defendants who have asserted defenses under the protocol. To date, Defendants have filed nineteen motions to dismiss or for summary judgment pursuant to the protocol with the Court.

The Court heard arguments on four of the motions, with respect to 22 Defendants, on May 14, 2024. On September 5, 2024, the Court granted summary judgment for defendants on the four motions on the grounds that the Trust's claims were barred by § 546(e) and that certain defendants were not transferees of the share repurchases. On September 19, 2024, the Trust filed with the District Court a notice of appeal and motion for leave to pursue an interlocutory appeal from the Bankruptcy Court's decision on the issue of whether Mallinckrodt's share repurchases could be protected from avoidance under § 546(e) when they were void ab initio under applicable nonbankruptcy law. Thereafter, the parties asked the Bankruptcy Court to issue a final judgment as to these four motions so that the Trust would have an appeal of right from the Bankruptcy Court's decision. The Bankruptcy Court issued the final judgment on January 13, 2025. On January 23, 2025, the Trust filed an amended notice of appeal. On May 19, 2025, the parties completed briefing on the merits. On August 20, 2025, the appeal was reassigned to Third Circuit Judge Bibas under 28 U.S.C. § 291(b) to hold a district court within the circuit.

The parties completed briefing on fourteen additional motions to dismiss or motions for summary judgment filed under the protocol where the sole issue in dispute is the issue that was on appeal, all of which the Court granted. The Court also granted in part and denied in part a summary judgment motion by a defendant that additionally alleged the Trust did not properly name it, an issue the Trust prevailed on.

On November 24, 2025, the District Court affirmed the Bankruptcy Court's order holding that the share repurchases were qualifying transactions protected by § 546(e) even though they were void ab initio under applicable non-bankruptcy law. The Trust declined to appeal the decision to the Third Circuit.

On January 29, 2026, the Trust entered into a stipulation with nine Defendants in favor of whom the Court had granted summary judgment where the sole issue in dispute was the

Opioid Master Disbursement Trust II

issue on appeal. Pursuant to the stipulation, which was filed with the Court, the parties asked the Court to convert the non-final judgments in favor of those Defendants to partial final judgments under Federal Rule of Civil Procedure 54(b).

Finally, the Trust has settled with 17 defendants for monetary consideration.

Opioid Master Disbursement Trust II

Exhibit A

Opioid Master Disbursement Trust II Background

The Opioid Master Disbursement Trust II was established pursuant to the chapter 11 Plan confirmed in the bankruptcy cases of Mallinckrodt plc, *In re Mallinckrodt plc*, Case No. 20-12522 (Bankr. D. Del.), confirmed by order dated March 2, 2022, and effective as of June 16, 2022 (the “2022 Plan”).

Pursuant to the 2022 Plan, MDT II was formed as a “hub” trust in a “hub & spoke” trust design, created to receive distributions (from funds paid by Mallinckrodt and any litigation recoveries) and then make distributions to the “spoke” beneficiary trusts: the Public Creditor Trusts (for the U.S. States and Territories and local governments within U.S. States and Territories, as well as the federally-recognized American Indian and Alaska Native Tribes) and the Private Creditor Trusts (for, e.g., personal injury victims, persons afflicted by neonatal abstinence syndrome, hospitals).

In the spring of 2023, following the rapidly deteriorating financial condition of Mallinckrodt and an aggressive letter-writing campaign by various stakeholders of the company, the MDT II Trustees determined that it was in the best interests of MDT II’s beneficiaries to engage in conversations with the company to restructure the remaining Opioid Deferred Cash Payments (which at the time totaled \$1.275 billion, and included the \$200 million payment that was due on June 16, 2023). Without a comprehensive deal, MDT II’s status as an unsecured creditor in a free fall bankruptcy would have left the trust subordinate to approximately \$3.5 billion in secured debt. Following weeks of intensive negotiations, MDT II, along with other key stakeholders, signed a restructuring support agreement (the “2023 RSA”) with the company on August 23, 2023, setting forth the terms of a prepackaged financial restructuring plan.

On August 28, 2023, Mallinckrodt commenced bankruptcy proceedings (see *In re Mallinckrodt plc*, Case No. 20-12522 (Bankr. D. Del.)), on October 10, 2023, its second Plan of Reorganization was confirmed, and on November 14, 2023, its second Plan of Reorganization went effective (the “2023 Plan”).

Pursuant to the 2023 RSA and 2023 Plan, MDT II received a one-time payment of \$250

Opioid Master Disbursement Trust II

million in full satisfaction of the remaining Opioid Deferred Cash Payments, and disbursed the full amount to the Public and Private Opioid Creditor Trusts, per the waterfall under the 2022 Plan, on August 29, 2023. MDT II also received enhanced cooperation under the Cooperation Agreement to facilitate the prosecution of the three MDT II third-party litigations (reducing costs for the Trust), and contingent value rights (“CVR”), essentially warrants, in the company (which subsequently provided \$35,000,000 in value when the Trust monetized this asset in November 2025).

The MDT II’s primary responsibilities are to: (i) receive the opioid settlement funds from Mallinckrodt (an obligation amended pursuant to the 2023 RSA and 2023 Plan); (ii) investigate and pursue claims against third parties that are assigned to the MDT II; (iii) fix a bar date and administer Other Opioid Claims that were not resolved as part of the Plan (a process that is still on-going); and (iv) make distributions to the Public and Private Creditor Trusts per the allocations in the Plan. These Opioid Creditor Trusts disburse funds received from MDT II to their respective creditors to be used for approved opioid abatement strategies or, in the case of the PI Trust, to compensate individuals for damages because of opioid-related bodily injuries.

More information about the Trust, including important documents, biographies of the MDT II Trustees (Jenni Peacock, Michael Atkinson, and Anne Ferazzi), and answers to frequently asked questions, can be found on the Trust’s website: <https://www.opioidmasterdisbursementtrust.com/Mallinckrodt>.

Opioid Master Disbursement Trust II

Appendix³

³ Note: Figures herein reflect Trust activity subsequent to the receipt and disbursement of the Initial Opioid Deferred Cash Payment where applicable. Expenses exclude fees incurred during the Period but unpaid as of January 31, 2026.

Opioid Master Disbursement Trust II

Appendix 1: Trust Financial Summary⁴

Trust Activity Summary for Eleventh Reporting Period (October 1, 2025 – January 31, 2026):

(\$ in actuals)	Beginning Balance	MDT II Period Receipts			MDT II Period Disbursements			Ending Balance
		Opioid Deferred Cash Payments	Interest and Other Income	Total Receipts	Distributions	Expenses (Litigation & Administrative)	Total Disbursements	
Operating Reserve	\$95,404,065	-	\$1,271,569	\$1,271,569	-	(\$3,741,610)	(\$3,741,610)	\$92,934,024
Third-Party Payor Reserve	-	-	-	-	-	-	-	-
Municipal and Tribe Opioid Attorneys' Fee Fund	-	-	-	-	-	-	-	-
Ratepayer Account	-	-	-	-	-	-	-	-
Opioid MDT II Total	\$95,404,065	-	\$1,271,569	\$1,271,569	-	(\$3,741,610)	(\$3,741,610)	\$92,934,024

Trust Activity Cumulative Summary (June 16, 2022 – January 31, 2026):

(\$ in actuals)	Beginning Balance	MDT II Cumulative Receipts			MDT II Cumulative Disbursements			Ending Balance
		Opioid Deferred Cash Payments	Interest and Other Income	Total Receipts	Distributions	Expenses (Litigation & Administrative)	Total Disbursements	
Operating Reserve	\$134,953,403	-	\$22,458,621	\$22,458,621	-	(\$64,478,000)	(\$64,478,000)	\$92,934,024
Third-Party Payor Reserve	29,363,667	-	-	-	(29,363,667)	-	(29,363,667)	-
Municipal and Tribe Opioid Attorneys' Fee Fund	11,276,655	11,303,789	2,464,723	13,768,512	(25,045,167)	-	(25,045,167)	-
Ratepayer Account	3,000,000	-	-	-	(3,000,000)	-	(3,000,000)	-
Opioid MDT II Total	\$178,593,724	\$11,303,789	\$24,923,344	\$36,227,133	(\$57,408,834)	(\$64,478,000)	(\$121,886,834)	\$92,934,024

⁴ Note: Receipt of CVR Agreement termination proceeds and subsequent distributions are not included in these "Trust Activity Summary for Eleventh Reporting Period" and "Trust Activity Cumulative Summary" appendices.

Opioid Master Disbursement Trust II

CVR Proceeds Distribution Detail (November 24, 2025):

Trust	Distribution
NOAT II	\$24,478,038.06
TAFT II	731,063.96
PI Trust (NAS PI / PI Opioid Claims Share)	3,434,050.00
Third-Party Payor Trust	1,920,616.65
Hospital Trust	1,235,220.00
Municipal and Tribe Opioid Attorneys' Fee Fund	1,540,556.23
State Opioid Attorneys' Fee Fund (NOAT II)	1,260,455.10
Total	\$34,600,000.000⁽¹⁾

⁽¹⁾ CVR Agreement termination proceeds of \$35,000,000 less \$400,000 of certain transaction costs

Opioid Master Disbursement Trust II

Trust Operating Reserve Additional Detail:

(\$ in actuals)

Beginning Cash

Professional Fees - Legal & Litigation Support

Trustee Fees & Expenses

Professional Fees - Financial

Insurance

Other

Total Trust Expenses

Interest and Other Income

Ending Cash

	Actual	Actual
	Jun 25 - Sep 25 <i>(4 months)</i>	Oct 25 - Jan 26 <i>(4 months)</i>
Beginning Cash	\$98,975,596	\$95,404,065
Professional Fees - Legal & Litigation Support	(4,331,928)	(3,339,306)
Trustee Fees & Expenses	(258,333)	(258,979)
Professional Fees - Financial	(100,000)	(100,000)
Insurance	(182,935)	-
Other	(40,539)	(43,325)
Total Trust Expenses	(\$4,913,735)	(\$3,741,610)
Interest and Other Income	1,342,203	1,271,569
Ending Cash	\$95,404,065	\$92,934,023

Opioid Master Disbursement Trust II

Appendix 2: Trust Budget

Pursuant to the 2022 Plan, Mallinckrodt was obligated to make 9 cash payments over 8 years on account of the Opioid Deferred Cash Payments. The scheduled payments totaled \$1,725,000,000, of which ~\$1,718,000,000 was to be paid to the Trust. However, given the Company's financial performance, an agreement was reached between the Company, its financial creditors and the Trust to settle all remaining Opioid Deferred Cash Payments for a final payment prior to its 2023 Chapter 11 filing. The Trust received a second and final payment of \$250,000,000 on August 24, 2023 which it then distributed to the opioid creditor trusts per the 2022 Plan.¹ In November 2025, the Trust distributed to the opioid creditor trusts \$34,600,000 of net proceeds that were received in exchange for termination of the CVR Agreement. The Trust may receive additional amounts on account of assigned litigation claims and interest income, but none of these amounts are certain nor can they be estimated at this time.

In the fourth year of its operations, the Trust is projected to disburse \$13,875,608 on account of its expenses (i.e., excluding disbursements to creditor trusts) comprised of \$12,369,564 for legal and litigation support, \$775,645 for trustee fees and expenses, \$300,000 for financial services, \$182,935 for insurance, and \$247,464 for other expenses.

¹ The Trust also received enhanced cooperation under the Cooperation Agreement to facilitate the prosecution of the three MDT II third-party litigations (reducing costs for the Trust) and contingent value rights ("CVR"), essentially warrants, in the company.

Opioid Master Disbursement Trust II

Trust Period Expense and Operating Budget:

(\$ in actuals)

	Actual	Actual	Forecast	Total
	Jun 25 - Sep 25 (4 months)	Oct 25 - Jan 26 (4 months)	Feb 26 - May 26 (4 months)	Jun 25 - May 26 (12 months)
Beginning Cash	\$98,975,596	\$95,404,065	\$92,934,023	\$98,975,596
Professional Fees - Legal & Litigation Support	(4,331,928)	(3,339,306)	(4,698,330)	(12,369,564)
Trustee Fees & Expenses	(258,333)	(258,979)	(258,333)	(775,645)
Professional Fees - Financial	(100,000)	(100,000)	(100,000)	(300,000)
Insurance	(182,935)	-	-	(182,935)
Other	(40,539)	(43,325)	(163,600)	(247,464)
Total Trust Expenses	(\$4,913,735)	(\$3,741,610)	(\$5,220,263)	(\$13,875,608)
Interest and Other Income	1,342,203	1,271,569	1,183,651	3,797,422
Ending Cash	\$95,404,065	\$92,934,023	\$88,897,411	\$88,897,411